UPDATE -- Clinipace Worldwide Executive Joins Board of Kidney Health Initiative
27 oct. 2017 09h42 HE
|
Clinipace Worldwide
MORRISVILLE, N.C., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Hampton Corley, Chief Business Officer of Clinipace Worldwide, a global full-service clinical research organization (CRO), has been appointed to...
Clinipace Worldwide Executive Joins Board of Kidney Health Initiative
27 oct. 2017 08h38 HE
|
Clinipace Worldwide
MORRISVILLE, N.C., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Hampton Corley, Chief Business Officer of Clinipace Worldwide, a global full-service clinical research organization (CRO), has been appointed to...
Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017
05 sept. 2017 07h45 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Second Quarter 2017 Financial Results
07 août 2017 17h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
02 août 2017 19h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces $22.0 Million Private Placement
22 juin 2017 09h31 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
15 juin 2017 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces First Quarter 2017 Financial Results
10 mai 2017 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
10 mai 2017 07h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
02 mai 2017 16h40 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...